Concepedia

Immunogenicity Endpoints

Immunogenicity Endpoints is a type of clinical trial endpoint that measures the magnitude and quality of the immune response elicited by a vaccine candidate, specifically distinguished by its focus on immunological biomarkers rather than clinical disease outcomes.

208

Publications

12.1K

Citations

2.2K

Authors

740

Institutions

Publications per year

2017–2026

88

Parents

Publications

208

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin et al. · Nature · 2020 · 1.6K citations · Full text

, , +17

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Robert Edelman, Carol O. Tacket, Steven S. Wasserman et al. · American Journal of Tropical Medicine and Hygiene · 2000 · 365 citations

, , +17

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

Xavier Castellsagué, Núbia Muñóz, Punnee Pitisuttithum et al. · British Journal of Cancer · 2011 · 346 citations · Full text

, , +17

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Brian J. Ward, Philipe Gobeil, Annie Séguin et al. · Nature Medicine · 2021 · 316 citations · Full text

, , +17

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

Alexandre Harari, Pierre‐Alexandre Bart, Wolfgang Stöhr et al. · The Journal of Experimental Medicine · 2008 · 294 citations · Full text

, , +17

1–5 of 208

Authors

2.2K

  1. WC
    William C. Gruber

    Pfizer (United States), United States

    6 publications · 2.2K citations

    6

    h-index

  2. KU
    Kathrin U. Jansen

    Pfizer (United States), United States

    5 publications · 2K citations

    5

    h-index

  3. PB
    Peter B. Gilbert

    Fred Hutch Cancer Center, United States

    5 publications · 250 citations

    5

    h-index

  4. BL
    Bruce L. Innis

    Walter Reed Army Institute of Research, United States

    4 publications · 180 citations

    4

    h-index

  5. EE
    Edward E. Walsh

    University of Rochester, United States

    4 publications · 1.9K citations

    4

    h-index

1–5 of 2.2K

Institutions

740

  1. GlaxoSmithKline (Belgium)

    Wavre, Belgium

    9 h-index

    23 publications

    752 citations

  2. Pfizer (United States)

    New York, United States

    8 h-index

    73 publications

    23.7K citations

  3. National Institutes of Health

    Bethesda, United States

    8 h-index

    22 publications

    1.8K citations

  4. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    7 h-index

    25 publications

    2.6K citations

  5. University of Maryland, Baltimore

    Baltimore, United States

    7 h-index

    11 publications

    4.2K citations

  6. University College London

    London, United Kingdom

    6 h-index

    13 publications

    386 citations

  7. Cincinnati Children's Hospital Medical Center

    Cincinnati, United States

    6 h-index

    6 publications

    2.1K citations

  8. Fred Hutch Cancer Center

    Seattle, United States

    6 h-index

    11 publications

    522 citations

1–8 of 740

Venues

  1. Vaccine

    40 publications · 2K citations

    25

    h-index

  2. Human Vaccines & Immunotherapeutics

    HV&I · 13 publications · 322 citations

    11

    h-index

  3. The Pediatric Infectious Disease Journal

    PIDJ · 8 publications · 192 citations

    8

    h-index

  4. The Journal of Infectious Diseases

    JID · 9 publications · 680 citations

    8

    h-index

  5. medRxiv

    Repository · 8 publications · 581 citations

    8

    h-index

1–5